American Regent v. Hikma Pharmaceuticals: Selenious Acid Patent Dispute Consolidated
American Regent, Inc. filed suit against Hikma Pharmaceuticals USA, Inc. in the District of New Jersey asserting US11998565B2, covering selenious acid injectable formulations used in parenteral nutrition. Within 128 days, the case was consolidated with 12 parallel actions against generic challengers into a single multi-defendant ANDA proceeding.
A coordinated ANDA strike: 13 generics face American Regent in one consolidated action
American Regent, Inc. (ARI), a pharmaceutical company and holder of US11998565B2 covering selenious acid injectable formulations delivering 60 mcg selenium/mL, filed suit against Hikma Pharmaceuticals USA, Inc. in the U.S. District Court for the District of New Jersey on July 16, 2024. The asserted patent protects specific concentration formulations of selenious acid used in intravenous parenteral nutrition — a clinically critical micronutrient therapy. The action followed Hikma’s filing of an Abbreviated New Drug Application (ANDA) seeking approval to market a generic equivalent.
The case closed on November 21, 2024 — 128 days after filing — not through a merits ruling or settlement, but via consolidation. ARI had simultaneously initiated 12 substantially identical infringement actions against other generic challengers including Accord Healthcare, Cipla, Dr. Reddy’s, Sun Pharma, and Zydus, among others. All parties stipulated to consolidate the 13 actions into a single proceeding captioned under Civil Action No. 2:24-cv-07791, streamlining litigation management before the same judge.
The speed of consolidation — under four months from first filing — suggests ARI and the generic defendants recognized early that coordinated case management was preferable to parallel, duplicative discovery and briefing schedules. The public record is silent on whether any licensing discussions accompanied the consolidation stipulation. All substantive patent validity and infringement questions remain open and will be resolved in the lead consolidated action, making the outcome here entirely procedural.
Filing to Case Consolidated in 128 days
128 days to consolidation — faster than the median ANDA case lifecycle in D.N.J.
Case consolidated: what the transfer to a unified docket means for both parties
Consolidation is procedural — no merits decided here
Under Federal Rule of Civil Procedure 42(a), courts may consolidate actions sharing common questions of law or fact. Here, all 13 ANDA actions involve the same patent (US11998565B2) and substantially identical product formulations. Consolidation does not resolve infringement or validity — it redirects all proceedings into a single docket (No. 2:24-cv-07791) to avoid duplicative discovery, inconsistent rulings, and judicial inefficiency.
FRCP 42(a) consolidationARI gains efficiency managing 13 generic challengers at once
Consolidation benefits American Regent by centralising all claim construction, expert discovery, and trial scheduling into one proceeding. ARI avoids the resource burden of litigating 13 parallel dockets and reduces the risk of inconsistent rulings on the same patent claims. However, ARI must now litigate against a coordinated group of generic defendants who may align their invalidity and non-infringement arguments, raising the complexity of defence.
Centralised enforcementHikma joined 12 co-defendants in a unified defence posture
For Hikma and its co-defendants, consolidation enables shared discovery, potentially shared expert witnesses, and coordinated claim construction briefing — reducing per-defendant litigation costs. The flipside is that individual defendants may have distinct ANDA product specifications or non-infringement arguments that could be diluted in a consolidated setting. The 30-month ANDA stay clock continues to run regardless of procedural posture.
Shared defence opportunitySelenium injectable market faces a multi-year enforcement hold
With 13 generic ANDAs now consolidated before a single New Jersey judge, FDA approval of any generic selenious acid injectable at the challenged concentrations is effectively stayed pending litigation outcome. For hospital formularies and parenteral nutrition suppliers, this suggests continued reliance on ARI’s branded product for the near term. The consolidated proceeding will set a single precedent on claim scope — making the eventual merits ruling commercially significant for the entire generic injectable nutrition market.
Generic market entry delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Specialty pharmaceutical company — holder of US11998565B2 for selenious acid injectablesSearch in Eureka ↗ |
| Defendant | Hikma Pharmaceuticals USA, Inc. | Company | U.S. subsidiary of Hikma Pharmaceuticals plc; generic and specialty injectable drug manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated consolidation order is entirely procedural in character — it reflects agreement among all parties that the 13 actions share common factual and legal questions sufficient to warrant unified management under FRCP 42(a). No finding of infringement, validity, or enforceability was made. The order’s reference to ‘good cause’ for consolidation is standard judicial language and carries no substantive weight on the merits. All patent claims under US11998565B2 remain live and unresolved in the lead docket (2:24-cv-07791).
US11998565B2 — Selenious Acid Injectable Formulations for Parenteral Nutrition
US11998565B2, filed under application number US18/124391, protects selenious acid injectable formulations at defined selenium concentrations — specifically 60 mcg selenium/mL (600 mcg/10 mL) and 6 mcg selenium/mL (12 mcg/2 mL). Selenium is an essential trace element administered intravenously to patients who cannot receive enteral nutrition, including critically ill, surgical, and neonatal patients. The patent’s concentration-specific claims suggest ARI has sought to protect particular formulation parameters that may relate to stability, dosing precision, or compatibility with parenteral nutrition admixtures.
In the parenteral micronutrient space, formulation patents covering specific concentration ranges and excipient profiles have become a primary competitive moat as small-molecule APIs themselves are long off-patent. US11998565B2 is strategically significant because it underpins ARI’s ability to block generic selenious acid injectables at the claimed concentrations from reaching the hospital market. With 13 ANDA filers challenging the product, the patent’s validity and claim scope will face rigorous scrutiny — and a finding of invalidity in the consolidated action would open the market simultaneously to all challengers.
Should your selenious acid injectable product be cleared against US11998565B2?
Any company developing, manufacturing, or commercialising intravenous selenious acid formulations — particularly at concentrations of 60 mcg/mL or 6 mcg/mL — should treat US11998565B2 as a material FTO risk. The consolidated New Jersey litigation confirms this patent is being actively enforced against at least 13 generic entrants. R&D and regulatory teams planning ANDA submissions or 505(b)(2) applications for selenium injectables should conduct claim-by-claim analysis before finalising formulation specifications.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US11998565B2 against your specific product formulation parameters — including concentration ranges, excipient profiles, and dosage forms — and surface prior art that may inform invalidity arguments or design-around options. Use Eureka to monitor the consolidated action (lead docket 2:24-cv-07791) for claim construction orders and PTAB filings that will materially affect your freedom to operate in the parenteral selenium market.
Run a freedom-to-operate analysis on US11998565B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: injectable pharmaceutical formulation disputes in D.N.J.
Explore related Paragraph IV infringement actions involving injectable pharmaceutical formulation patents litigated in the District of New Jersey.
What this case signals for the injectable pharmaceutical IP landscape
ARI’s coordinated 13-defendant filing strategy sets a template for aggressive ANDA defence in the parenteral nutrition space.
Simultaneous multi-defendant ANDA filing is now a standard enforcement playbook
American Regent’s decision to file 13 parallel infringement actions on the same day — triggering automatic 30-month stays across all ANDAs — signals a deliberate enforcement strategy. Patent holders in the injectable pharmaceutical space should model this approach when facing a wave of generic entrants on a single branded formulation.
Consolidation does not reset the 30-month ANDA stay — timing still matters
Each defendant’s 30-month stay clock runs from the date ARI received their individual Paragraph IV notice letter, not from the consolidation order. Generic entrants and branded companies alike must track per-defendant stay expiry dates independently, even within a consolidated proceeding. Missing a stay expiry can result in premature FDA approval or launch risk.
American v Hikma — key questions answered
The case was not decided on the merits. It was closed on November 21, 2024 after being consolidated with 12 parallel ANDA infringement actions into a single proceeding under Case No. 2:24-cv-07791 in the District of New Jersey. All substantive patent questions remain pending in that lead consolidated action.
American Regent asserts US11998565B2, filed under application number US18/124391. The patent covers selenious acid injectable formulations at specific selenium concentrations — 60 mcg/mL and 6 mcg/mL — used in intravenous parenteral nutrition therapy.
Consolidation under FRCP 42(a) occurs when multiple actions share common questions of law or fact. Here, American Regent filed 13 near-identical ANDA infringement suits on the same patent against different generic manufacturers. The court consolidated all actions into one docket to avoid duplicative proceedings and the risk of inconsistent rulings. No merits determination was made in Case No. 2:24-cv-07803.
The consolidated action involves 13 defendants including Hikma Pharmaceuticals USA, Accord Healthcare, Aspiro Pharma, Cipla USA, Cipla Limited, Dr. Reddy’s Laboratories, Eugia Pharma, Gland Pharma, Long Grove Pharmaceuticals, RK Pharma, Somerset Therapeutics, Sun Pharmaceutical Industries, Xiromed, and Zydus Pharmaceuticals. All proceedings are now under lead docket No. 2:24-cv-07791.
Consolidation is a procedural case management tool and does not alter the 30-month stay mechanism under the Hatch-Waxman Act. Hikma’s 30-month stay period runs from the date American Regent received Hikma’s Paragraph IV certification notice, independent of the consolidation order. FDA approval of Hikma’s ANDA remains stayed for the duration of that period unless litigation concludes earlier.
PatSnap Eureka searches patents and litigation data to answer instantly.